These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23161645)

  • 1. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial.
    Aaron SD; Vandemheen KL; Maltais F; Field SK; Sin DD; Bourbeau J; Marciniuk DD; FitzGerald JM; Nair P; Mallick R
    Thorax; 2013 Feb; 68(2):142-8. PubMed ID: 23161645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.
    Aaron SD; Vandemheen KL; Hebert P; Dales R; Stiell IG; Ahuja J; Dickinson G; Brison R; Rowe BH; Dreyer J; Yetisir E; Cass D; Wells G
    N Engl J Med; 2003 Jun; 348(26):2618-25. PubMed ID: 12826636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.
    Dougados M; Combe B; Braun J; Landewé R; Sibilia J; Cantagrel A; Feydy A; van der Heijde D; Leblanc V; Logeart I
    Ann Rheum Dis; 2010 Aug; 69(8):1430-5. PubMed ID: 20511606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
    Leuppi JD; Schuetz P; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Müller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J
    JAMA; 2013 Jun; 309(21):2223-31. PubMed ID: 23695200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
    Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
    Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.
    Raghu G; Brown KK; Costabel U; Cottin V; du Bois RM; Lasky JA; Thomeer M; Utz JP; Khandker RK; McDermott L; Fatenejad S
    Am J Respir Crit Care Med; 2008 Nov; 178(9):948-55. PubMed ID: 18669816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation.
    Freeman BJ; Ludbrook GL; Hall S; Cousins M; Mitchell B; Jaros M; Wyand M; Gorman JR
    Spine (Phila Pa 1976); 2013 Nov; 38(23):1986-94. PubMed ID: 24165696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
    Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
    Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
    van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
    Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.
    Morjaria JB; Chauhan AJ; Babu KS; Polosa R; Davies DE; Holgate ST
    Thorax; 2008 Jul; 63(7):584-91. PubMed ID: 18245148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
    Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
    Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.